MLF2

Across TCGA pan-cancer cohorts, MLF2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MLF2 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MLF2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MLF2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where MLF2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.393	0.735	.004	39	view →
LSCC	DFS	Median	All	0.976	0.890	.003	9	view →
UCEC	OS	Quartile	All	0.836	1.000	.017	6	view →
LUAD	OS	Median	III,IV	0.663	1.000	.007	6	view →
GBM	DFS	Quartile	All	0.870	0.572	.008	5	view →
PDAC	OS	Median	II,III,IV	0.404	0.552	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MLF2–CCRCC (DFS)

Open the CCRCC breakdown →